TON November 2015 Vol 8 No 6

The Cancer Clinical Trials Office (CCTO) at Stanford University, Palo Alto, CA, oversees a large clinical trials program. Read More ›

The 2015 European Cancer Congress (ECC 2015) was held in Vienna, Austria, from September 25 to 29. The congress was jointly sponsored by the European CanCer Organisation (ECCO) and the European Society for Medical Oncology (ESMO). Read More ›

At the Academy of Oncology Nurse & Patient Navigators (AONN+) Sixth Annual Conference, held in Atlanta, GA, in October, Barbara Antolino-Smith, RN, BSN, CPN, Pediatric Oncology Nurse, Penn State Hershey Children’s Hospital, PA, was the recipient of the 2015 Oncology Nurse Excellence (ONE) Award. Read More ›

Results from a new study provide reassurance to women with cancer during pregnancy that they can be safely treated during the second or third trimester with chemotherapy/radiation without compromising their unborn child. Read More ›

The Oncology Nurse-APN/PA (TON), we feature Stanford Cancer Clinical Trials Office. Andrea F. Plati, MSN, RN, OCN, Associate Director of Clinical Research Operations, took the time to speak with us about her role, challenges, and exciting trials she is undertaking. Read More ›

The study of cancer survivorship includes the impact of cancer on family members, friends, and caregivers. Here is some information on a few aspects of cancer survivorship. Read More ›

At the 16th Annual International Lung Cancer Congress, Tony Mok, MD, Professor of Clinical Oncology at the Chinese University of Hong Kong, provided an overview of the next generation of agents, taking stock of the recent past for insights into the future of drug discovery. Read More ›

Molecular pathways in cancer can be exploited for therapy, and sensitizing genetic aberrations are the ideal targets, said Alex Adjei, MD, PhD, at PMO Live 2015, the annual joint meeting of the Global Biomarkers Consortium and the World Cutaneous Malignancies Congress. Read More ›

Patients with early breast cancer and a low Oncotype DX Recurrence Score (RS) can be safely treated with hormone therapy alone and avoid chemotherapy, according to results of the National Cancer Institute–sponsored Trial Assigning Individualized Options for Treatment (Rx), or TAILORx trial. Read More ›

Recent advances in predictive and prognostic molecular biomarkers promise to enhance precision medicine in oncology. A rundown of the progress being made in bioinformatics, genetics, and proteomics for this purpose was delivered by several speakers at PMO Live 2015, the annual joint meeting of the Global Biomarkers Consortium and the World Cutaneous Malignancies Congress. Read More ›

Page 1 of 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: